Literature DB >> 1681232

HIV transmission by stabbing despite zidovudine prophylaxis.

P D Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1681232     DOI： 10.1016/0140-6736(91)91535-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  [Postexposure prevention after occupational exposure to HBV, HCV and HIV].

Authors:  U Sarrazin; R Brodt; C Sarrazin; S Zeuzem
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

2.  Risks to surgeons and patients from HIV and hepatitis: guidelines on precautions and management of exposure to blood or body fluids. Joint Working Party of the Hospital Infection Society and the Surgical Infection Study Group.

Authors: 
Journal:  BMJ       Date:  1992-11-28

Review 3.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

Review 4.  Human immunodeficiency virus and hepatitis--implications for operating room personnel.

Authors:  S Colbert; G J Sheehan
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

5.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 7.  Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases.

Authors:  Arnaud Tarantola; Dominique Abiteboul; Anne Rachline
Journal:  Am J Infect Control       Date:  2006-08       Impact factor: 2.918
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.